HOME >> MEDICINE >> NEWS
Long-term study demonstrated ADDERALL XR is an effective option to treat adolescents with ADHA

Washington, DC, October 20, 2004 Shire Pharmaceuticals Group plc (NASDAQ: SHPGY, LSE: SHP.L, TSE: SHQ CN) announced today that ADDERALL XR (an extended release, mixed salts amphetamine product) is effective and generally well-tolerated for adolescents with attention-deficit/hyperactivity disorder (ADHD). The short- and long-term study results of the multicenter Phase 3 study were presented today in Washington, DC.

"To date, well-designed, controlled studies of ADHD medications in adolescents have been extremely rare," said lead investigator Stephen Grcevich, M.D., Case Western Reserve University School of Medicine and President and Founder of The Family Center by the Falls, in Chagrin Falls, Ohio. "While the vast majority of safety and efficacy studies with ADHD medications have been conducted in school age children, and more recently, in adult populations, physicians are being asked with increasing frequency to treat adolescents with significant functional impairment associated with ADHD. For this reason, it is critically important to access this long-term data to guide physicians in our treatment of this specific population group."

ADHD is considered the most commonly diagnosed psychiatric disorder in children and adolescents, and affects approximately three to seven percent of all school-age children, or approximately two million children in the U.S. Results from follow-up studies of subjects with ADHD published over the past two decades suggest that up to 80 percent of children diagnosed with ADHD will continue to exhibit symptoms in adolescence and up to 65 percent in adulthood.-

The three main symptoms of ADHD include inattention, hyperactivity and impulsivity. If left untreated, these symptoms may seriously and adversely affect patients as well as their families and friends. Findings from a national survey, "Capturing America's Attention," released earlier this year found that adults with ADHD tend to report lower educ
'"/>

Contact: Marion E. Glick
917-301-4206
Porter Novelli
20-Oct-2004


Page: 1 2 3

Related medicine news :

1. Long-term high consumption of red and processed meat linked with increased risk for colon cancer
2. Long-term data show benefit of DETROL LA as first-line therapy for overactive bladder
3. Long-term benefits for newly diagnosed patients with CML receiving first-line therapy with imatinib
4. Long-term obesity linked to loss of brain tissue in women
5. Long-term study proves ADDERALL XR is a safe and effective option to treat adults with ADHD
6. Long-term use of antibiotics possibly linked with increased risk of breast cancer
7. Long-term follow-up of mortality in patients with community-acquired pneumonia
8. Long-term outcome of epilepsy surgery is favorable for many
9. Long-term ERT in postmenopausal women with Alzheimers may worsen memory
10. Long-term avoidance of milk in children results in poor bone health
11. Long-term effects of tirofiban similar to abciximab in patients having coronary-artery angioplasty

Post Your Comments:
(Date:11/24/2014)... California (PRWEB) November 24, 2014 ... USD 6.19 billion by 2020, according to a ... incidence rates of cardiac arrhythmias clubbed with growing ... of this market. Though still in the budding ... significant rise in usage rates in the recent ...
(Date:11/24/2014)... November 24, 2014 Volpara Solutions ... 1.2 at the 100th Annual Meeting of the ... 5, 2014 (RSNA Booth 1752 – South Hall). ... VolparaAnalytics and the rest of its innovative suite ... VolparaDoseRT, which enable personalized measurements of volumetric density, ...
(Date:11/24/2014)... 24, 2014 Residents of retirement communities ... this year’s SENIORS GOT TALENT, an annual online talent ... piano players to classic crooners, to seniors partying on ... adults are indeed living young. , “SENIORS GOT TALENT, ... a cash prize, has always been about highlighting the ...
(Date:11/24/2014)... TX (PRWEB) November 24, 2014 Olaparib ... ribose polymerase (PARP) and is one of the first ... vulnerable to creating some types of melanoma, and are ... this also sometimes gives their malignancies a exclusive weaknesses, ... PARP to fix their DNA and allow them to ...
(Date:11/24/2014)... The Holiday Inn Westbury - Long ... Children's Association to donate various items consisting of ... other such items.The Association's program is aimed toward helping ... in nursing homes, assisted living facilities and nursing homes. ... being of seniors throughout the Long Island area. The ...
Breaking Medicine News(10 mins):Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 2Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 3Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 4Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 2Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3
(Date:11/22/2014)... Pharmaceuticals today announced positive preliminary results from a Phase 1 ... to 200 mg at bedtime had no next-day impairment of ... Annual Fall Scientific Meeting of the Sexual Medicine Society ... Miami . The Phase 1 driving study ... the Formal Dispute Resolution that was filed in December 2013. ...
(Date:11/22/2014)... Nov. 21, 2014   Long Beach dentist , Dr. ... called the gold standard in tooth replacement because they offer ... long-lasting way to restore and preserve smiles and improve overall ... a missing tooth or as a part of a smile ... and feel of a smile. The loss of ...
(Date:11/22/2014)... 21, 2014 Research and Markets  has announced ... Industry Report, 2014-2017" report to their offering. ... Chinese recombinant protein drug market has been expanding rapidly ... and the like. During 2005-2013, sales of recombinant protein ... CAGR of 19.1%, and it is projected that ...
Breaking Medicine Technology:Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3Long Beach Dentist, Dr. Rassouli, is Now Offering Dental Implants 2China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3
Cached News: